Related Experiment Video
Updated: Jun 7, 2026
04:29
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
[Epilepsy treatment by vagus nerve stimulation]
Christian Pilebaek Hansen1, Per Sidenius, Jesper Gyllenborg
1Epilepsihospitalet Filadelfia, 4293 Dianalund, Denmark. cphn@filadelfia.dk
Ugeskrift for Laeger
|November 9, 2010
Summary
For epilepsy patients unresponsive to medication, vagus nerve stimulation (VNS) offers an effective treatment option. VNS is well-tolerated and can improve quality of life, suggesting wider application for drug-resistant epilepsy.
Area of Science:
- Neurology
- Neurosurgery
- Medical Devices
Context:
- Epilepsy affects a significant portion of the population, with a substantial percentage experiencing drug-resistant seizures.
- Current treatments, including antiepileptic drugs, are ineffective for a considerable number of patients.
- Severe consequences of uncontrolled seizures necessitate alternative therapeutic strategies.
Purpose:
- To evaluate the role of vagus nerve stimulation (VNS) as a treatment for patients with drug-resistant epilepsy.
- To highlight the potential benefits of VNS in epilepsy management.
- To advocate for increased VNS utilization in suitable patient populations.
Summary:
- A significant proportion of epilepsy patients (25-33%) do not achieve seizure freedom with antiepileptic drugs.
- Epilepsy surgery is recommended for patients with severe, intractable seizures when feasible.
- Vagus nerve stimulation (VNS) is presented as an effective alternative for patients unsuitable for or unresponsive to surgery, applicable across all epilepsy syndromes and seizure types.
- VNS demonstrates a favorable safety profile and potential to enhance mood and quality of life.
Impact:
- Vagus nerve stimulation (VNS) presents a viable and well-tolerated therapeutic option for drug-resistant epilepsy.
- Wider adoption of VNS could improve seizure control and quality of life for many epilepsy patients.
- The study suggests that more epilepsy patients in Denmark should be considered for VNS therapy.
Related Concept Videos
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:30Electroconvulsive Therapy
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:13Seizures: Classification
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
01:22Epilepsy ll: Types
Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.